Price Chart

Profile

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of  bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
URL https://www.merus.nl
Investor Relations URL https://ir.merus.nl/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Oct. 31, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of  bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
URL https://www.merus.nl
Investor Relations URL https://ir.merus.nl/
HQ State/Province N/A
Sector Health Care
Industry Biotechnology
Equity Style Mid Cap/Blend
Next Earnings Release Feb. 28, 2025 (est.)
Last Earnings Release Oct. 31, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A